Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Draft Guidance On Drug Development For Early Alzheimer's A Call For Action On Biomarkers

Executive Summary

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease offers options for trial design, but without biomarkers to accurately diagnose the disease and track its progression, a trial could be doomed from the start.

You may also be interested in...



Alzheimer’s Drugs Take Baby Steps Toward Brighter Future

Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.

Jury Still Out On Beta Amyloid Target In Early Alzheimer’s

New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.

CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement

Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.

Related Content

Topics

UsernamePublicRestriction

Register

PS055101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel